CF
GLUE icon

Corebridge Financial’s Monte Rosa Therapeutics GLUE Stock Holding History

Corebridge Financial’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,233
Closed -$93.9K – 1115
2025
Q1 		$93.9K Sell
20,233
-300
-1% -$1.84K ﹤0.01% 2472
2024
Q4 		$142K Sell
20,533
-1,550
-7% -$11.6K ﹤0.01% 2364
2024
Q3 		$117K Buy
22,083
+5,689
+35% +$28.7K ﹤0.01% 2533
2024
Q2 		$61.3K Buy
+16,394
New +$83.6K ﹤0.01% 2834

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Corebridge Financial's GLUE Position: Q2 2025 in Review

Corebridge Financial sold out of Monte Rosa Therapeutics (GLUE) in Q2 2025, closing a stake of 20,233 shares — an estimated $93.9K sold.

Corebridge Financial first reported a position in GLUE in Q2 2024 and held it in 4 quarters. The position peaked at $142K in Q4 2024. 116 funds tracked by Wall St. Rank hold GLUE as of Q2 2025.

  • Corebridge Financial reported no remaining Monte Rosa Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 20,233 Monte Rosa Therapeutics shares in Q2 2025, an estimated $93.9K.
  • Corebridge Financial first reported a position in Monte Rosa Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Monte Rosa Therapeutics position peaked at $142K in Q4 2024.
  • 116 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.